Search

Displaying results 4501 - 4510 of 5383 in total
  1. Drug

    Omega-3 fatty acids

    go.drugbank.com/drugs/DB11133
    ApprovedInvestigationalNutraceutical

    α-linolenic acid (ALA) (found in plant oils), eicosapentaenoic acid (EPA), and docosahexaenoic acid (DHA) (both commonly found in fish oil that originally come from microalgae that is further consumed by

  2. Drug

    Manidipine

    go.drugbank.com/drugs/DB09238
    ApprovedInvestigationalWithdrawn

    Manidipine (INN) is a calcium channel blocker (dihydropyridine type) that is used clinically as an antihypertensive. It is selective for vasculature and does not produce effects on the heart at clinically relevant dosages.

  3. Drug

    PS386113

    go.drugbank.com/drugs/DB05211
    Experimental

    It is being developed by Schering-Plough and Pharmacopeia. Little information has been released about PS386113.

  4. Drug

    FB-101

    go.drugbank.com/drugs/DB17956
    Investigational

    Developed by 1st Biotherapeutics, it is being investigated for the treatment of neurological disorders, such as Parkinson's Disease and amyotrophic lateral sclerosis (ALS).[L47102]

  5. Drug

    DiaPep 277

    go.drugbank.com/drugs/DB06651
    Investigational

    DiaPep 277 is a 24-mer laboratory-made peptide derived from Hsp60(437-460).

  6. Drug

    Alethine

    go.drugbank.com/drugs/DB05800
    Investigational

    Alethine is studied in the treatment of cancer. It belongs to a family of chemicals called disulfides. It is a low molecular weight disulfide that has been shown to exhibit in vivo antitumor activity in murine myeloma and melanoma models.

  7. Drug

    Raseglurant

    go.drugbank.com/drugs/DB05070
    Investigational

    ADX10059 is a metabotropic glutamate receptor 5 (mGluR5) negative allosteric modulator (NAM). The orally available small molecule drug candidate, which is highly specific for mGluR5, was discovered at Addex in 2003. It is developed for t...

  8. Drug

    TTP889

    go.drugbank.com/drugs/DB05131
    Investigational

    TTP889, an orally bioavailable selective inhibitor of the intrinsic coagulation pathway, is being developed as an anticoagulant for the treatment of thromboembolic disorders. TTP889 is the only known selective small molecule inhibitor of...

  9. Drug

    Brentuximab

    go.drugbank.com/drugs/DB05471
    Investigational

    Brentuximab (SGN-30) is an engineered monoclonal antibody (mAb) that reacts with significant affinity to the CD30 antigen, which is highly expressed on a variety of hematologic malignancies as compared to on normal cells. SGN-30 has been...

  10. Drug

    T487

    go.drugbank.com/drugs/DB05474
    Experimental

    T487 is a small molecule chemokine receptor antagonist to correct or modify immune system responses. It binds selectively and potently to CXCR3. The formulation is administered orally and has anti-inflammatory effects in conditions such ...